Insider · CIK 0002102360
BX Mozart ML-2 Holdco L.P.
Files at MDLN (Medline Inc.). First filing Mar 12, 2026, latest Jun 1, 2026.
In brief
BX Mozart ML-2 Holdco L.P. files SEC Form 4 as 10% owner at MDLN (Medline Inc.). Since Mar 12, 2026, BX Mozart ML-2 Holdco L.P. has reported 0 open-market buys worth $0 and 2 open-market sells worth $2.3B, the latest filed on Jun 1, 2026.
A track record needs three past buys with six months of prices behind them; BX Mozart ML-2 Holdco L.P. has 0, so none is measured yet.
The newest scored trade: sold $1.2B of MDLN on May 28, 2026, filed Jun 1, 2026, scored 62 (notable). In the last 12 months: 0 buys worth $0 and 2 sells worth $2.3B.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MDLN: Medline Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 62Notable | Medline Inc. | $1.2B 33,317,824 shares | -30% | +3% from low-26% from high | |
| 57Moderate | Medline Inc. | $1.1B 27,852,986 shares | -22% | +10% from low-14% from high |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 28, 2026 | MDLN Medline Inc. | SOpen-market sale Class A Common Stockindirect: See Footnotes | -19,712,326 | $36.54 | $720M | 89,537,913 | Jun 1, 2026 |
| May 28, 2026 | MDLN Medline Inc. | SOpen-market sale Class A Common Stockindirect: See Footnotes | -9,858,774 | $36.54 | $360M | 10,185 | Jun 1, 2026 |
| May 28, 2026 | MDLN Medline Inc. | SOpen-market sale Class A Common Stockindirect: See Footnotes | -2,256,800 | $36.54 | $82M | 10,250,904 | Jun 1, 2026 |
| May 28, 2026 | MDLN Medline Inc. | SOpen-market sale Class A Common Stockindirect: See Footnotes | -1,489,924 | $36.54 | $54M | 1,539 | Jun 1, 2026 |
| May 28, 2026 | MDLN Medline Inc. | JOther Class A Common Stockindirect: See Footnotes | -438,214 | - | - | 1,990,467 | Jun 1, 2026 |
| Mar 10, 2026 | MDLN Medline Inc. | SOpen-market sale Class A Common Stockindirect: See Footnotes | -16,479,083 | $40.51 | $668M | 109,250,239 | Mar 12, 2026 |
| Mar 10, 2026 | MDLN Medline Inc. | SOpen-market sale Class A Common Stockindirect: See Footnotes | -8,241,723 | $40.51 | $334M | 10,185 | Mar 12, 2026 |
| Mar 10, 2026 | MDLN Medline Inc. | SOpen-market sale Class A Common Stockindirect: See Footnotes | -1,886,636 | $40.51 | $76M | 12,507,704 | Mar 12, 2026 |
| Mar 10, 2026 | MDLN Medline Inc. | SOpen-market sale Class A Common Stockindirect: See Footnotes | -1,245,544 | $40.51 | $50M | 1,539 | Mar 12, 2026 |
| Mar 10, 2026 | MDLN Medline Inc. | JOther Class A Common Stockindirect: See Footnotes | -366,337 | - | - | 2,428,681 | Mar 12, 2026 |
Questions about BX Mozart ML-2 Holdco L.P.
Answered from the filings on this page, as of the latest one.
Is BX Mozart ML-2 Holdco L.P. buying or selling?
In the last 12 months BX Mozart ML-2 Holdco L.P. reported 0 open-market buys worth $0 and 2 open-market sells worth $2.3B on SEC Form 4; the latest was sold $1.2B of MDLN on May 28, 2026. Grants, option exercises and tax withholding are not counted.
How did BX Mozart ML-2 Holdco L.P.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and BX Mozart ML-2 Holdco L.P. has 0.
Where does BX Mozart ML-2 Holdco L.P. file Form 4?
BX Mozart ML-2 Holdco L.P. has filed Form 4 at MDLN (Medline Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.